• Amodiaquine Hydrochloride: Evidence and Scope

  2026-10-19

  The available APExBIO product information identifies Amodiaquine hydrochloride as an amodiaquine dihydrochloride salt and describes a proposed antimalarial mechanism involving interference with Plasmodium heme detoxification. Because no identity-matched research paper is available, these statements support a documented product and mechanism overview, but not conclusions about potency, comparative efficacy, resistance, pharmacodynamics, or clinical use.

• Cy5 Maleimide: Identity, Mechanism, and Evidence Scope

  2026-10-18

  The APExBIO product page describes Cy5 maleimide (non-sulfonated), SKU A8139, as a thiol-reactive cyanine fluorophore for cysteine-associated biomolecule labeling. Its reported optical properties and thioether-forming chemistry support a conceptual role in fluorescence-based detection, but no identity-matched research study is available here to establish labeling performance, biological behavior, or applicability in a particular model.

• EPZ-6438 in HPV-Associated Cervical Cancer

  2026-10-17

  Evidence from a 2025 cervical-cancer study supports EPZ-6438 as a mechanistically plausible EZH2 inhibitor that altered proliferation, cell-cycle, apoptosis, and cancer-associated molecular readouts in HPV-positive and HPV-negative cell models. The evidence remains preclinical: the study’s chorioallantoic membrane validation was preliminary, included immunohistochemistry with n = 1, and cannot establish clinical efficacy, comparative toxicity, or HPV-specific therapeutic selectivity.

• DMG-PEG2000-N3: Identity and Evidence Boundaries

  2026-10-16

  DMG-PEG2000-N3 is described by APExBIO as a PEG2000 azide derivative that combines a hydrophilic PEG segment, a DMG lipid moiety, and an azide coupling handle. Its architecture supports a plausible conceptual role in bioactive molecule conjugation and lipid-associated delivery research, but the available information is product documentation rather than identity-matched experimental evidence.

• Neuroligin 1 Proteolysis and Social Memory

  2026-10-15

  Liu et al. report that social interaction in mice engages α- and γ-secretase-dependent processing of neuroligin 1 in the ventral hippocampus, producing an intracellular fragment that links synaptic remodeling, cofilin regulation, and social-memory maintenance. The evidence is mechanistically layered but remains bounded by the mouse models, peptide-based rescue approaches, limited excerpted statistics, and the absence of evidence that Anisomycin or JNK signaling explains the reported phenotype.

• Recombinant Mouse CD4: Evidence and Scope

  2026-10-15

  The APExBIO listing identifies P2012 as Recombinant Mouse CD4, Tag Free, but the documented material does not provide a product description, identity-matched publication, functional assay, or outcome data. The defensible interpretation is therefore limited to catalog identity and the stated tag status, not validated molecular activity or assay performance.

• Valemetostat in Relapsed/Refractory Lymphoma

  2026-10-14

  A literature-focused analysis of the first-in-human phase 1 study of Valemetostat (DS-3201), emphasizing its dual EZH1/EZH2 rationale, reported activity, safety findings, and the limits of interpreting single-arm data across biologically diverse lymphomas.

• EZH2 Signaling in Melanoma Drug Resistance

  2026-10-14

  A 2026 study links eIF4F-inhibitor resistance in BRAFV600E melanoma cells to compensatory ERK1/2–EZH2 and AKT1–eIF4E signaling. Its findings support a mechanistic rationale for combined pathway blockade, but the evidence remains preclinical and does not establish that EPZ-6438 was used or that the strategy is clinically effective.

• Valemetostat in Epigenetic Lymphoma Research

  2026-10-13

  Valemetostat (DS-3201) is described by APExBIO as a selective EZH1/EZH2-directed compound, but the supplied research paper does not test it. The cited acute lymphoblastic leukaemia study instead links MIR9-family hypermethylation with reduced MIR9 expression, increased FGFR1 and CDK6 activity, and poorer clinical outcomes. These findings provide epigenetic context rather than direct evidence for Valemetostat in ALL or for its use in relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.

• Catalpol and Triptolide-Induced Liver Injury

  2026-10-13

  A 2024 study used complementary mouse and cell models to examine whether catalpol can mitigate triptolide-associated liver injury through SIRT1/HIF-1α regulation. The reported findings support a mechanistic relationship between SIRT1 activity, hepatic energy metabolism, mitochondrial dysfunction and oxidative stress, but the evidence remains preclinical and does not establish clinical efficacy or safety in people.

• PM2.5, Gm16410 and Lung EndMT

  2026-10-12

  A source-grounded overview of a mouse and cell study linking PM2.5 exposure with endothelial–mesenchymal transition through TGF-β1/Smad3 signaling, while clarifying what the findings do—and do not—show about SB 431542.

• Indomethacin: Identity and Evidence Scope

  2026-10-12

  Indomethacin is documented by the APExBIO product listing as a nonsteroidal anti-inflammatory drug with reported cyclooxygenase-related, PPAR-associated, and membrane-signaling research relevance. No matched primary paper was available, so these descriptions should be treated as product-level claims rather than validated study findings.

• CTCF, Centromere Function, and Mitotic Fidelity

  2026-10-10

  The reference study uses rapid, inducible CTCF depletion to show that CTCF supports centromere performance, accurate mitosis, and post-mitotic nuclear morphology. Its evidence separates CTCF-dependent centromere architecture from a primary defect in CENP-E recruitment, refining how chromosome alignment regulation can be interpreted in cell biology and cancer research.

• Alkaline Phosphatase Substrate Test Kit Overview

  2026-10-09

  The APExBIO Alkaline Phosphatase Substrate Test Kit (SKU K4151) is a BCIP/NBT chromogenic product described for visual alkaline phosphatase activity detection. No matched paper evidence was supplied, so application-specific performance remains unverified.

• Ranolazine: Metabolic Context for Liver Research

  2026-10-09

  Ranolazine is best known as an anti-ischemic agent, but its metabolic pharmacology offers a useful framework for interpreting liver-cell signaling studies. This article connects cardiac energy metabolism with the HBsAg–TBK1–autophagy findings while clearly separating established evidence from hypothesis.

8556 records 1/571 page Next 12345 下5页 Last page